Phazemos Blog
Key Words
- Bioinformatics
- Biotech
- Business Development
- Clinical Consultancy
- Consultants
- Device Comany
- Economical Model
- Investor
- Med Device
- Partner Development
- Pharma
- Pre-seed Round
- Proven Support
- Reputation
- SMO
- Save Money
- Save Time
- Seed Round
- Service Provider
- Small Business Owner
- Strategi Expansion
- Strategic Partnerships
- Strategy
- Synthetic Control Arm
- Technology
Developing Business within the Phazemos Ecosystem
Collaboration is key. At Phazemos, we excel at fostering partnerships that drive innovation and growth. This blog will examine how two members of the Phazemos network effectively leveraged our services to achieve their distinct objectives.
Are rising costs threatening your clinical development goals?
We know how essential it is to meet your deadlines and stay within budget—without sacrificing quality. We’ve built a trusted ecosystem that connects biotech, pharma, and med device companies with a network of top-tier, small to mid-sized providers, offering expert solutions at a fraction of the cost of traditional CROs.
Bridging the Gap in Bioinformatics for Small Biotech Companies
Small biotech companies often face the challenge of integrating sophisticated bioinformatics solutions into their operations. Here's how we help specialized bioinformatics find its place in serving these companies.
Phazemos Helped Find the Right Investment Partner
A promising biotech company reached out to Phazemos with a goal to raise a $3 million seed round. They needed a partner who could not only provide the necessary capital but also add value through industry expertise and strategic connections. Our task was clear, and we were ready to leverage our flexible Match Program to make it happen.
Identifying an Acquisition Target in a Crowded Market
A promising startup approached Phazemos seeking assistance in raising a $250,000 pre-seed round. They needed targeted support to identify the right investor capable of kickstarting their ambitious growth plan. Read how we helped.